Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Lymphoma 7Lymphoma, Follicular 6Lymphoma, Non-Hodgkin 5Lymphoma, Large B-Cell, Diffuse 4Lymphoma, B-Cell, Marginal Zone 4Lymphoma, Mantle-Cell 3Recurrence 2Advanced Malignancies 2Unresectable or Metastatic Solid Tumors 1Pancreatic Neoplasms 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell 1Lung Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms 1B-Cell Malignancies 1

Interventions

romidepsin 12Cyclophosphamide 11Vincristine 9Rituximab 9Etoposide 9Lenalidomide 8Doxorubicin 8Brentuximab Vedotin 8fludarabine 6Prednisone 6Peripheral Blood Stem Cell Transplantation 6Melphalan 6Depsipeptides 6fludarabine phosphate 5Mycophenolic Acid 5Lactones 5Gemcitabine 5Cytarabine 5Bendamustine Hydrochloride 5Antilymphocyte Serum 5Whole-Body Irradiation 4Tacrolimus 4Sirolimus 4Methotrexate 4MLN 8237 4Carmustine 4Bortezomib 410-propargyl-10-deazaaminopterin 4thymoglobulin 3duvelisib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lymphoma, T-Cell × parsaclisib × Clear all
NCT04774068 2025-01-17

Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
5 enrolled
DermatologicLymphoid

Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡